




Contents lists available at ScienceDirect

## Respiratory Investigation

journal homepage: [www.elsevier.com/locate/resinv](http://www.elsevier.com/locate/resinv)



### Statement

# Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society] <sup>☆</sup>



Hitoshi Tokuda<sup>a,\*</sup>, Masayoshi Harigai<sup>b</sup>, Hideto Kameda<sup>c</sup>, Kazunori Tomono<sup>d</sup>, Noboru Takayanagi<sup>e</sup>, Akira Watanabe<sup>f</sup>, Sadatomo Tasaka<sup>g</sup>, Takafumi Suda<sup>h</sup>, Kazuhiro Tateda<sup>i</sup>, Junichi Kadota<sup>j</sup>

<sup>a</sup>Department of Respiratory Medicine, Tokyo Yamate Medical Center, Department of Respiratory Medicine, Tokyo Yamate Medical Center, 3-22-1 Hyakunin-cho, Shinjuku-ku, Tokyo 169-0073, Japan

<sup>b</sup>Department of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 173-0004, Japan

<sup>c</sup>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, 2-17-6 Ohashi, Meguro-ku, Tokyo 153-8515 Japan

<sup>d</sup>Infection Control Team, Osaka University Hospital, 2-15 Yamadaoka, Suita-shi, Osaka 565-0871, Japan

<sup>e</sup>Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, 1696 Itai, Kumagaya-shi, Saitama 360-0105, Japan

<sup>f</sup>Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan

<sup>g</sup>Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki-shi, Aomori 036-8562, Japan

<sup>h</sup>Second Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handacho, Higashi-ku, Hamamatsu-shi, Shizuoka 431-3129, Japan

<sup>i</sup>Department of Microbiology and Infectious Disease, Toho University School of Medicine, 5-21-16 Omorinishi, Ota-ku, Tokyo 143-8540, Japan

<sup>j</sup>Department of Respiratory medicine and Infectious diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka Hasama-machi Yufu, 879-5593, Japan

Abbreviations: MTX, methotrexate; TNF, tumor necrosis factor; IL, interleukin; CTLA4, cytotoxic T-lymphocyte antigen 4; IFX, infliximab; ADA, adalimumab; GLM, golimumab; CZP, certolizumab pegol; ETN, etanercept; TCZ, tocilizumab; ABA, abatacept; RTX, rituximab; UTK, ustekinumab; PCP, *Pneumocystis jirovecii* pneumonia; NTM, nontuberculous mycobacteria; IMID, immune-mediated inflammatory disease; anti-CCP antibody, anti-cyclic citrullinated peptide antibody

<sup>\*</sup>This article is based on an abridged edition of consensus statements first published as Consensus Statements for Medical Practice-Biological Agents and Lung Disease by the Japanese Respiratory Society in Japanese in February 2014.

<sup>\*</sup>Corresponding author. Fax: +81 3 3364 5663.

E-mail addresses: [tokuda@car.ocn.ne.jp](mailto:tokuda@car.ocn.ne.jp) (H. Tokuda), [harigai.masayoshi@twmu.ac.jp](mailto:harigai.masayoshi@twmu.ac.jp) (M. Harigai), [hideto.kameda@med.toho-u.ac.jp](mailto:hideto.kameda@med.toho-u.ac.jp) (H. Kameda), [tomono@hp-infect.med.osaka-u.ac.jp](mailto:tomono@hp-infect.med.osaka-u.ac.jp) (K. Tomono), [takayanagi.noboru@pref.saitama.lg.jp](mailto:takayanagi.noboru@pref.saitama.lg.jp) (N. Takayanagi), [akira.watanabe.b3@tohoku.ac.jp](mailto:akira.watanabe.b3@tohoku.ac.jp) (A. Watanabe), [tasaka@hirosaki-u.ac.jp](mailto:tasaka@hirosaki-u.ac.jp) (S. Tasaka), [suda@hama-med.ac.jp](mailto:suda@hama-med.ac.jp) (T. Suda), [kazu@med.toho-u.ac.jp](mailto:kazu@med.toho-u.ac.jp) (K. Tateda).

<http://dx.doi.org/10.1016/j.resinv.2017.01.002>

2212-5345/© 2017 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

## ARTICLE INFO

## Article history:

Received 24 November 2016

Accepted 22 January 2017

Available online 29 March 2017

## Keywords:

Biological agent

Lung complication

Airway disease

Interstitial lung disease

Rheumatoid arthritis

## Contents

1. Introduction . . . . .	231
2. Part I. Basic considerations . . . . .	232
2.1. Overview of biological agents . . . . .	232
2.1.1. Outline . . . . .	232
2.1.2. Characteristics and efficacy of biological agents approved in Japan for autoimmune diseases . . . . .	232
2.1.3. Safety of biological agents . . . . .	233
3. Characteristics of patients (recipients) subject to biological agents—a focus on rheumatoid arthritis . . . . .	234
3.1. Introduction . . . . .	234
3.2. Pathology and immunological abnormalities of immune-mediated inflammatory diseases including RA . . . . .	234
3.3. Immune response to biological agents . . . . .	234
3.4. Prognosis and prognosticators for RA . . . . .	234
3.5. Points to be considered by pulmonologists during up-to-date RA treatment . . . . .	235
4. RA-associated lung comorbidities as a risk factor for pulmonary complications—focusing on airway diseases . . . . .	235
4.1. Introduction . . . . .	235
4.2. RA and airway diseases . . . . .	235
4.3. Bronchiectasis . . . . .	235
4.4. Bronchiolitis . . . . .	236
4.5. Airway disease and lung infection . . . . .	237
4.6. Airway disease and treatment strategies of RA . . . . .	237
5. Why does infection occur more frequently following the administration of biological agents? . . . . .	237
5.1. Introduction . . . . .	237
5.2. Infections that occur more frequently following the administration of biological agents . . . . .	237
6. Part 2. Individual problems . . . . .	238
6.1. Bacterial infections . . . . .	238
7. Mycobacterial infection . . . . .	240
7.1. Tuberculosis . . . . .	240
7.2. Nontuberculous mycobacterial disease . . . . .	242
7.2.1. Introduction . . . . .	242
8. <i>Pneumocystis pneumonia</i> . . . . .	244
8.1. Introduction . . . . .	244
9. Conclusions . . . . .	245
10. Interstitial pneumonia . . . . .	245
11. Respiratory complications in patients with diseases other than rheumatoid arthritis for which biological agents are used . . . . .	247
11.1. Introduction . . . . .	247
Conflict of interest . . . . .	248
References . . . . .	248

Download English Version:

<https://daneshyari.com/en/article/8750811>

Download Persian Version:

<https://daneshyari.com/article/8750811>

[Daneshyari.com](https://daneshyari.com)